Some researchers believe that the expression of PR is a better marker for responding to hormone therapy compared to estrogen, while in the recent study and Kolude et al. [ 20], the level of PR expression was not high, and it is not possible to establish a relationship between the level of expression of the marker and microscopic types and tumor progression. The gene discussed is PGR; the disease is neoplasm.